Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder, a Double-blind, Placebo-controlled Study

NCT00318539 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00318539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00318539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder, a Double-blind, Placebo-controlled Study
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
August 31, 2006
Enrollment
90
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obsessive compulsive disorder